Navigating Anticoagulation Decisions in Atrial Fibrillation and Frailty Comorbidity

Frailty is highly prevalent in older patients with atrial fibrillation (AF), complicating anticoagulation decisions due to the dual elevation of both stroke and bleeding risks. This narrative review provides a framework to guide these decisions. We propose a three-step approach: (1) systematically assess frailty using a validated tool to stratify patients into risk categories; (2) translate this stratification into therapeutic choices, generally favoring direct oral anticoagulants (DOACs) over warfarin, with data suggesting a favorable bleeding profile for apixaban in frail populations, but routine switching to a DOAC should be avoided in frail patients who are stable on warfarin with good time in therapeutic range; and (3) consider specific alternatives, such as very-low-dose edoxaban, for patients with severe frailty or a prohibitive bleeding risk, while noting that this strategy should be applied within its specific regulatory and clinical context. The net clinical benefit of anticoagulation, defined as the absolute risk reduction in ischemic stroke offset by the absolute risk increase in major bleeding, diminishes with increasing frailty severity and may vanish in the most severe stages. Clinical decisions must therefore integrate dynamic frailty reassessment, multidisciplinary collaboration, and patient preferences. This review underscores a shift from purely guideline-driven to patient-value-driven individualized anticoagulation strategies in frail older adults with AF.